Key Highlights

  • Arovella released the first two clinical batches of ALA-101 during September 2026, enough material to complete dose escalation and begin dose expansion.
  • The Alfred and Epworth Hospital trial sites are active and screening patients, with first patient dosing expected in October.
  • Net operating cash outflow for the quarter was A$2.7 million, leaving cash of A$11.6 million at 30 September 2026.
  • An FY26 R&D tax incentive rebate of A$4.03 million received in October lifts the pro forma cash balance to about A$15.63 million.

Arovella Therapeutics Limited (ASX:ALA) reported that it reached clinical readiness for its lead cell therapy, ALA-101, during the September 2026 quarter. The company released its first two manufactured batches for patient use, activated two clinical trial sites and began screening patients for a first-in-human study.

ALA-101 is an allogeneic CD19-targeting CAR-iNKT cell therapy being tested in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and certain leukaemias. Arovella said its priority is to obtain preliminary clinical safety and efficacy data in blood cancers while advancing its second program, ALA-105, toward the clinic.

Off-the-Shelf Manufacturing and Trial Start-Up

ALA-101 is made from healthy donor-derived invariant natural killer T (iNKT) cells using a scalable Good Manufacturing Practice process. Multiple doses can be produced ahead of time and stored as off-the-shelf clinical supply, so treatment can proceed once screening and other clinical requirements are met rather than waiting for patient-specific manufacturing. The two released batches provide enough material to complete dose escalation and begin dose expansion. In addition to its engineered CD19 CAR, ALA-101 retains natural iNKT recognition pathways, including recognition of glycolipid antigens presented by CD1d and of stress ligands through NKG2D. Arovella notes that any advantages in tumour targeting, safety, access and cost remain subject to clinical evaluation.

The ALA-101-001 trial is a dose-escalation and expansion study designed to assess safety and tolerability, determine a dose for further development and generate preliminary evidence of anti-tumour activity. The Alfred and Epworth Hospital sites are active, and two more are being activated to support recruitment. The company expects to dose the first patient in October.

Regulators require a 28 day wait between dosing the first three patients, and again for the first patient at each dose increase, to observe any adverse safety signals. Screening can continue during those windows. By the end of the first quarter of calendar 2027, Arovella expects to have completed dosing at the first dose level, started the second and be enrolling at a faster pace.

ALA-105 Animal Data and Near-Term Milestones

In vivo animal studies of ALA-105, the armoured CLDN18.2-directed CAR-iNKT program, are progressing, with results expected within weeks. The company said the data will inform whether ALA-105 continues toward the clinic. The studies are intended to show anti-tumour activity in animal models, and the program targets claudin 18.2.

For the final quarter of calendar 2026, Arovella listed five milestones: dosing the first ALA-101 patient, completing the in vivo efficacy studies, generating initial clinical data including CD19-positive B cell depletion, preparing regulatory filings to expand ALA-101 into autoimmune disease, and starting IND-enabling non-clinical and manufacturing work for ALA-105.

Management activity during the quarter included an investor webinar on 12 August hosted by Bell Potter, attendance at the Bioshares Biotech Summit in Queenstown from 5 to 7 August, and participation by Acting CEO Dr Nicole van der Weerden in the Cell and Gene Meeting on the Mesa in Phoenix from 5 to 7 October, where she and a colleague held more than 30 one-on-one meetings.

Cash Flow and Funding Position

Arovella ended September 2026 with cash and cash equivalents of A$11.602 million, down from A$14.353 million at the start of the quarter. Net operating cash outflow was A$2.732 million. Payments for research and development were A$1.720 million, staff costs were A$825,000 and administration and corporate costs were A$304,000, while interest received added A$143,000. Research and development and staff costs made up 89% of operating outflows.

The cash balance comprised A$1.537 million in bank balances and A$10.065 million in call deposits. On 22 October 2026 the company announced an FY26 R&D tax incentive rebate of A$4.03 million, received in October, which brings the pro forma cash position to about A$15.63 million before cash movements since quarter-end. Payments to related parties totalled A$57,500 for non-executive directors.

Where the Numbers Leave the Company

Arovella reports no financing inflows or investing outflows for the quarter, so the movement in cash reflects operating activity alone. Item 8.5 of the Appendix 4C estimates 4.2 quarters of funding at the current operating outflow, based on A$11.602 million of available funding and no unused facilities. With the October rebate added, the pro forma balance of about A$15.63 million sits alongside the first dosing, ALA-105 animal data and regulatory preparation scheduled for the coming months.